01
Risk-Stratified Surveillance
Positive findings allow physicians to recommend personalized screening protocols including earlier MRI, colonoscopy intervals, enhanced imaging, or preventive interventions before cancer develops.
Hereditary Cancer Genomics (CGx)
Precision Germline Testing for Physicians Nationwide
US Biosciences performs hereditary cancer genomic testing exclusively on the PacBio Vega™ HiFi long-read sequencing platform, helping physicians identify inherited cancer risk, guide treatment decisions, and provide patients with personalized prevention and surveillance strategies.
Ready to Order Hereditary Cancer Genomics Testing?
Download the official US Biosciences CGx Test Requisition Form.
📄 Download CGx Test Requisition Form
Overview
Earlier Detection Begins with Better Genetics.
Hereditary cancer syndromes account for approximately 5 to 10 percent of all cancer diagnoses, yet many at-risk patients remain unidentified until after cancer develops. Germline genetic testing gives clinicians the opportunity to identify pathogenic or likely pathogenic variants before disease occurs, allowing surveillance and preventive strategies to begin much earlier.
For patients already diagnosed with cancer, hereditary genomic testing can help stratify inherited risk, guide treatment decisions, identify eligibility for targeted therapies, and provide valuable information for family members who may also be at increased risk.
US Biosciences performs hereditary cancer genomic testing exclusively on the PacBio Vega™ HiFi long-read sequencing platform. Our comprehensive multi-gene panels are designed around current evidence-based clinical guidelines and are aligned with NCCN recommendations as well as Medicare and commercial payer medical necessity requirements.
CGx Test Snapshot
- Specimen: Buccal swab
- Platform: PacBio Vega™ HiFi long-read sequencing
- Comprehensive hereditary cancer gene panels
- Supports treatment selection and inherited risk assessment
- NCCN guideline aligned testing strategy
- Medicare and commercial payer medical necessity support
Why Providers Order CGx
Earlier Answers. Better Treatment Decisions. Lifelong Value.
Hereditary Cancer Genomics helps physicians identify inherited cancer risk, personalize treatment strategies, and provide meaningful guidance for patients and their families.
02
Treatment Guidance
Variants in genes such as BRCA1 and BRCA2 can help determine eligibility for targeted therapies including PARP inhibitors and platinum-based chemotherapy strategies.
03
Family Cascade Testing
A single hereditary cancer diagnosis provides actionable information for first- and second-degree relatives, allowing additional family members to pursue genetic counseling and preventive care.
04
Evidence-Based Panels
Multi-gene panels are built around current NCCN recommendations and evidence-based hereditary cancer guidelines to support confident clinical decision making.
05
Documentation Built In
Our requisition is structured around ICD-10 medical necessity criteria for Medicare and commercial payers, helping reduce claim friction while supporting compliant ordering.
06
Precision Reports
Reports include clinically significant variants, gene-specific clinical interpretation, evidence-based recommendations, and patient-friendly summaries that support counseling and ongoing care.
Technology Advantage
Powered by PacBio Vega™ HiFi Long-Read Sequencing
HiFi long-read sequencing delivers exceptional accuracy across difficult genomic regions, enabling more complete hereditary cancer analysis than many conventional short-read sequencing platforms.
Clinical Confidence
Greater Confidence in Every Variant.
PacBio Vega™ HiFi technology generates highly accurate long reads capable of resolving repeat-rich regions, structural variants, and complex genomic sequences that are often challenging for traditional short-read methods.
This provides physicians with greater confidence in hereditary cancer results, helping reduce false negatives, improve variant detection, and deliver more complete genetic information for treatment planning, surveillance, and family counseling.
Common Clinical Applications
- Hereditary breast cancer
- Ovarian cancer risk assessment
- Prostate cancer genetics
- Pancreatic cancer syndromes
- Lynch syndrome and colorectal cancer
- Hereditary neuroendocrine tumor syndromes
Available Panels
Comprehensive Hereditary Cancer Testing Panels
Specimens are collected using a simple buccal swab. Every panel is performed exclusively on the PacBio Vega™ HiFi long-read sequencing platform for exceptional accuracy and comprehensive variant detection.
| Panel | Clinical Indication | Key Genes |
|---|---|---|
| BRCA1 & BRCA2 | Targeted hereditary breast and ovarian cancer testing when focused BRCA status is required for treatment decisions, including PARP inhibitor eligibility. | BRCA1, BRCA2 |
| Hereditary Breast, Ovarian, Prostate, Pancreatic & Endometrial | Patients with a personal or family history meeting hereditary cancer testing criteria. | ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, STK11, TP53 and additional clinically relevant hereditary cancer genes. |
| Hereditary Colon Cancer | Lynch syndrome, familial adenomatous polyposis, Cowden syndrome, and inherited colorectal cancer syndromes. | APC, ATM, AXIN2, BLM, BMPR1A, CHEK2, EPCAM, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, RPS20, SMAD4, STK11, TP53 and additional genes. |
| Hereditary Neuroendocrine Tumor | Evaluation of hereditary endocrine tumor syndromes including pheochromocytoma, paraganglioma, MEN1, MEN2, parathyroid adenoma, and related conditions. | CDKN1B, EPCAM, MAX, MEN1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TSC1, TSC2, VHL |
Frequently Asked Questions
Hereditary Cancer Genomics Questions
Common questions physicians ask when considering hereditary cancer genomic testing.
Who is an appropriate candidate for hereditary cancer genomic testing?
Appropriate candidates include patients with a personal history of breast, ovarian, colorectal, pancreatic, prostate, endometrial, or neuroendocrine cancers, especially when diagnosed at younger ages. Individuals with significant family histories may also qualify under current clinical guidelines.
How is US Biosciences CGx testing different?
All hereditary cancer testing is performed exclusively on the PacBio Vega™ HiFi long-read sequencing platform, providing superior accuracy across difficult genomic regions, improved structural variant detection, and greater confidence than many traditional short-read sequencing methods.
What specimen is required?
Standard collection utilizes a simple buccal swab that can be performed in virtually any healthcare setting without requiring blood collection, making testing convenient for providers and patients.
How does billing and insurance work?
US Biosciences accepts Medicare, Medicaid, and most commercial insurance plans. Our requisition captures the documentation necessary to support medical necessity, and self-pay options are available when appropriate.
What information is included in the report?
Reports include clinically significant variants classified using ACMG/AMP criteria, gene-specific interpretation, recommended follow-up considerations, and patient-friendly summaries that support physician counseling and long-term care planning.
Ready to Order CGx?
Bring Advanced Hereditary Cancer Testing to Your Practice
Connect with a US Biosciences representative to discuss hereditary cancer genomic testing, provider onboarding, ordering requirements, payer documentation, and clinical implementation.